Log in to search using one of your social media accounts:

 

Flow Cytometry Assesses Minimal Residual Disease in Myeloma
MRD assessment with flow cytometry is a rapidly developing area of research (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 30, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pathology, Journal, Source Type: news

Insights from a rare genetic disease may help treat multiple myeloma
(American Chemical Society) A new class of drugs for blood cancers such as leukemia and multiple myeloma is showing promise. But it is hobbled by a problem that also plagues other cancer drugs: targeted cells can develop resistance. Now scientists, reporting in ACS Central Science, have found that insights into a rare genetic disease known as NGLY1 deficiency could help scientists understand how that resistance works -- and potentially how drugs can outsmart it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 25, 2017 Category: International Medicine & Public Health Source Type: news

Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS ® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
Once-Weekly KYPROLIS at 70 mg/m2 Shows Superior Efficacy and Comparable Safety to Twice-Weekly KYPROLIS at 27 mg/m2 Positive Results From Pre-Specified Interim Analysis THOUSAND OAKS, Calif., Oct. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered once-weekly at the 70 mg/m2 dose with dexamethasone allowed relapsed and refractory multiple myeloma patients to live 3.6 months longer without their disease worsening than KYPROLIS administered twice-weekly at the 27 mg/m2 dose with dexamethasone. The ov...
Source: Amgen News Release - October 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Medical News Today: Leukemia: Cancer cells killed off with diabetes drug
Researchers find that boosting fat cells in the bone marrow using a diabetes drug not only kills off leukemic cells, but it also regenerates healthy ones. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 16, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

How Common Is Multiple Myeloma?
Title: How Common Is Multiple Myeloma?Category: Doctor's& Expert's views on SymptomsCreated: 10/13/2017 12:00:00 AMLast Editorial Review: 10/13/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 13, 2017 Category: Cancer & Oncology Source Type: news

SMC approves daratumumab for myeloma patients in Scotland
The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex) to treat myeloma patients on National Health Service (NHS) Scotland. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 10, 2017 Category: Pharmaceuticals Source Type: news

Myeloma UK initiates MUK nine clinical trial for myeloma
Non-profit organisation Myeloma UK has initiated an MUK nine clinical trial that will use genetic techniques to stratify therapy for high-risk myeloma patients in the country. (Source: Drug Development Technology)
Source: Drug Development Technology - October 10, 2017 Category: Pharmaceuticals Source Type: news

Lenalidomide Boosts Overall Survival After Stem Cell Tx (CME/CE)
(MedPage Today) -- Now considered a standard of care for multiple myeloma patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 10, 2017 Category: Hematology Source Type: news

Is Multiple Myeloma Curable?
Title: Is Multiple Myeloma Curable?Category: Doctor's& Expert's views on SymptomsCreated: 10/9/2017 12:00:00 AMLast Editorial Review: 10/9/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 9, 2017 Category: Cancer & Oncology Source Type: news

How Many Stages of Multiple Myeloma Are There?
Title: How Many Stages of Multiple Myeloma Are There?Category: Doctor's& Expert's views on SymptomsCreated: 10/3/2017 12:00:00 AMLast Editorial Review: 10/3/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 3, 2017 Category: Cancer & Oncology Source Type: news

What Is the Life Expectancy of Someone with Multiple Myeloma?
Title: What Is the Life Expectancy of Someone with Multiple Myeloma?Category: Doctor's& Expert's views on SymptomsCreated: 10/2/2017 12:00:00 AMLast Editorial Review: 10/2/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 2, 2017 Category: Cancer & Oncology Source Type: news

bluebird bio starts treatment in Phase I trial for multiple myeloma
bluebird bio has started treating patients in a Phase I clinical trial (CRB-402) of its investigational candidate bb21217 for relapsed or refractory multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news

Bloomfield receives Outstanding Clinician-Scientist Award
(Ohio State University Wexner Medical Center) Clara D. Bloomfield, MD, Distinguished University Professor, cancer scholar and senior advisor to The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, has received the 2017 Robert A. Kyle Award for Outstanding Clinician-Scientist. The award was presented by the Mayo Clinic's Division of Hematology to recognize outstanding contributions in the diagnosis and treatment of hematologic cancers, which include leukemias, lymphomas and multiple myeloma (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 28, 2017 Category: International Medicine & Public Health Source Type: news

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement
Roche: Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study be placed on partial clinical hold. (Source: Roche Investor Update)
Source: Roche Investor Update - September 15, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: MDS symptoms: What are the signs of pre-leukemia?
MDS, or myelodysplastic syndrome, refers to a group of blood cancers. In this article, learn about the symptoms and complications of this disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 15, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

FDA Extends Holds in Immunotherapy Trials in Blood Cancers FDA Extends Holds in Immunotherapy Trials in Blood Cancers
The Food and Drug Administration has slowed or fully halted more trials of immunotherapies in multiple myeloma and other blood cancersMedscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Halts Enrollment in Nivolumab Myeloma Trials
(MedPage Today) -- Clinical hold follows similar action for pembrolizumab (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 7, 2017 Category: American Health Source Type: news

Bristol-Myers says FDA places partial hold on Opdivo myeloma trials
(Reuters) - The U.S. Food and Drug Administration has placed a partial hold on three clinical trials testing Bristol-Myers Squibb's immunotherapy Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies involving a rival drug, the company said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - September 6, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

UK NICE issues second draft ‘no’ on Ninlaro to treat myeloma patients
The UK National Institute for Health and Care Excellence (NICE) has issued a second draft ‘no’ on Takeda’s Ninlaro (ixazomib) for the treatment of patients with relapsed or refractory myeloma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 5, 2017 Category: Pharmaceuticals Source Type: news

FDA Alert Over Multiple Myeloma Trials With Pembrolizumab FDA Alert Over Multiple Myeloma Trials With Pembrolizumab
The FDA has issued a statement about the increased risk for death that was observed when pembrolizumab was added to multiple myeloma regimens in clinical trials.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Reiterates Keytruda Not for Use in Multiple Myeloma
(MedPage Today) -- Warning comes two months after pembrolizumab trials halted due to deaths (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 31, 2017 Category: American Health Source Type: news

Medical News Today: Acute myeloid leukemia: Heart drugs may boost chemotherapy
Researchers find that drugs normally used to treat heart and blood vessel disease could also help to improve chemotherapy outcomes for patients with AML. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Statement from Center for Drug Evaluation and Research Director Janet Woodcock regarding safety concerns related to investigational use of Keytruda in multiple myeloma
(Source: Food and Drug Administration)
Source: Food and Drug Administration - August 31, 2017 Category: American Health Source Type: news

Amgen ’s long-term analysis of Kyprolis’ ENDEAVOR trial shows favourable data
Amgen has reported positive data from a long-term analysis of the Phase III ENDEAVOR trial of Kyprolis (carfilzomib) for the treatment of relapsed or refractory multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS ® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
ENDEAVOR Study Long-Term Data Shows KYPROLIS and Dexamethasone Reduced the Risk of Death by 24 Percent Versus Velcade® (Bortezomib) and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 9.0 Months Longer Than Patients Receiving Velcade and Dexamethasone Long-Term Follow-Up Demonstrated Consistent Safety Profile THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three y...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS ® (Carfilzomib) Label
FDA Sets PDUFA Target Action Date of April 30, 2018 THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on the overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial demonstrating that KYPROLIS® (carfilzomib) and dexamethasone (Kd) reduced the risk of death by 21 percent and increased OS by 7.6 months versus Velcade® (bortezomib) and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (median OS 47.6 mon...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Overall Survival Analysis From KYPROLIS ® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology
KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Compared to Velcade® (bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients KYPROLIS is the First and Only Multiple Myeloma Therapy Proven to Extend Overall Survival in a Head-to-Head Comparison With a Current Standard of Care in the Relapsed Setting THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS® (...
Source: Amgen News Release - August 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Reduced Retreatment Dose Feasible in Relapsed, Refractory Multiple Myeloma
Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen. (Source: CancerNetwork)
Source: CancerNetwork - August 19, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Mainstream media finally starting to ask why TURMERIC isn't being promoted as a safe, affordable treatment for CANCER
(Natural News) A common kitchen staple has saved the life of a 57-old woman who had been battling blood cancer for five years. After undergoing three rounds of chemotherapy and four stem cell transplants to treat myeloma, Dieneke Ferguson thought she had exhausted all her options. Myeloma develops when the white blood cells produced in... (Source: NaturalNews.com)
Source: NaturalNews.com - August 17, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Vitamin C may stop leukemia from progressing
New research finds that high-dose vitamin C can genetically 'reprogram' leukemic cells to mature and die normally, instead of replicating to cause cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 17, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Survival Benefit in Myeloma With Lenalidomide Maintenance After Transplant
Patients with newly diagnosed multiple myeloma treated with lenalidomide maintenance therapy after undergoing autologous stem-cell transplantation had significantly improved overall survival compared with observation or placebo. (Source: CancerNetwork)
Source: CancerNetwork - August 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Roswell Park-Led Analysis Shows Survival Benefit of Lenalidomide...
New research analysis published in JCO definitively shows an overall survival benefit from ongoing treatment with lenalidomide for patients with multiple myeloma who have already received bone marrow...(PRWeb August 15, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14605233.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 15, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Leukemia: Mushroom protein could be used in future treatments
A protein found in the edible mushroom commonly known as " shaggy ink cap " has the potential to kill leukemia T cells, a new study suggests. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Latest Immunotherapy Approaches in Multiple Myeloma
This video highlights novel approaches using immunotherapies and vaccines for advancing treatment in multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - August 12, 2017 Category: Cancer & Oncology Authors: Ivan Borrello, MD Tags: Multiple Myeloma Videos Hematologic Malignancies Source Type: news

Test results after stem cell transplant for multiple myeloma can confuse patients and doctors about cancer's status
(Medical College of Georgia at Augusta University) It's a cancer of the plasma cells, which normally make an array of antibodies that protect us from infection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 10, 2017 Category: Cancer & Oncology Source Type: news

PharmaMar starts a quadruple combination study with Aplidin for the treatment of multiple myeloma
(Pharmamar) PharmaMar announced the start of a multicenter quadruple combination clinical study with Aplidin ® (plitidepsina), along with other compounds for the treatment of multiple myeloma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

SMC approves Amgen ’s carfilzomib for multiple myeloma treatment
The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen ’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Health Service (NHS) Scotland. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

New science confirms eating turmeric every day reverses cancer
(Natural News) A report in the British Medical Journal illustrates how a woman has beaten blood cancer with the help of turmeric. In 2007, 67-year-old Dieneke Ferguson was diagnosed with myeloma and she progressed to stage three within 15 months. Three failed rounds of chemotherapy and four failed stem cell transplants later, doctors told her... (Source: NaturalNews.com)
Source: NaturalNews.com - August 4, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Leukemia breakthrough: Blood molecule key to treating AML
Heme, a chemical structure found in hemoglobin, is key to treating acute myeloid leukemia, an aggressive form of blood cancer, researchers have discovered. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 4, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Blood cancer breakthrough: Disease could be treated with THIS commonly prescibed drug
BLOOD cancer, which includes leukaemia, lymphoma and myeloma, could be cured with an arthritis drug - believed to cost less than a pound a week. (Source: Daily Express - Health)
Source: Daily Express - Health - August 3, 2017 Category: Consumer Health News Source Type: news

Science journal confirms eating turmeric cured myeloma cancer in 57-year-old woman
(Natural News) After undergoing three rounds of chemotherapy and four stem cell transplants and still finding herself sick and weak, blood cancer patient, Dieneke Ferguson, believed she reached the end of her tether. She was told she had exhausted all her options. “Nothing worked: there was just too much cancer….there was nothing else I could... (Source: NaturalNews.com)
Source: NaturalNews.com - July 31, 2017 Category: Consumer Health News Source Type: news

Revlimid drives Celgene profit beat; raises EPS forecast
(Reuters) - Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Turmeric helped a dying woman beat cancer
Dieneke Ferguson, 67, of North London, was diagnosed with the blood cancer myeloma in 2007 and underwent three rounds of chemotherapy as well as four stem cell transplants. (Source: the Mail online | Health)
Source: the Mail online | Health - July 25, 2017 Category: Consumer Health News Source Type: news

NICE approves new tolerable drug carflizomib for multiple myeloma patients on NHS
UK ’s National Institute for Health and Care Excellence (NICE) has approved Amgen’s new anti-cancer treatment carflizomib for multiple myeloma patients on the National Health Service (NHS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 23, 2017 Category: Pharmaceuticals Source Type: news

FDA Halts Pembrolizumab Trials in Multiple Myeloma
The US Food and Drug Administration (FDA) placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma: KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS ® (Carfilzomib) Label
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients THOUSAND OAKS, Calif., July 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing application to the European Medicines Agency (EMA) to include overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in the product information fo...
Source: Amgen News Release - July 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial
Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news

Second Phase 3 Study Shows KYPROLIS ® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 7.9 Months Longer Than Patients on Lenalidomide and Dexamethasone KYPROLIS-Based Regimens Are the First and Only to Demonstrate Improved Overall Survival Versus Today's Standards of Care in Two Phase 3 Studies in Relapsed Multiple Myeloma THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint ...
Source: Amgen News Release - July 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Rapid, Durable Responses in Advanced Myeloma With Daratumumab Combo
Treatment with the combination of daratumumab plus pomalidomide/dexamethasone resulted in rapid, deep, and sustained responses with no new safety signals in patients with heavily treated multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - July 12, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

SECOND OPINION | Did Canadians get a caloric kick from NAFTA?
Did Canadians consume more high-fructose corn syrup after the North American free trade deal lowered tariffs on the sweetener? Also two immunotherapy trials for multiple myeloma patients are cancelled and a new pathogen is linked to Lyme disease. (Source: CBC | Health)
Source: CBC | Health - July 8, 2017 Category: Consumer Health News Tags: News/Health Source Type: news